Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04612374 · ClinicalTrials.gov registry record · NA
Exploring the Acceptability and Efficacy of a Transdiagnostic Treatment for Misophonia
A NA study of Misophonia, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT04612374: Completed NA study of Misophonia, sponsored by Duke University.
NCT04612374 is a NA study of Misophonia that has completed, run by Duke University. The registered enrollment target is 18 participants, below the 56-participant average among 7 other Misophonia trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04612374, a NA study of Misophonia, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
Despite increasing recognition of misophonia, there are currently no evidence-based treatments to help those who are suffering. Therefore, the primary purpose of this study is to assess the acceptability, feasibility, and preliminary efficacy of a treatment for misophonia. This study will be conducted in two phases. In the Phase 1, participants will receive a treatment the investigators believe can help manage symptoms of misophonia: The Unified Protocol. This treatment uses evidence-based psychological principles (e.g., managing attention or behavior) in a flexible manner and will focus on developing skills to help reduce the distress and impairment associated with Misophonia. After treatment, patients will provide feedback about their experience. The investigators will use this feedback to revise the treatment as indicated. In Phase 2, participants will receive the revised treatment and provide feedback on their experience. Throughout treatment in either phase, participants will provide daily and weekly information about their symptoms. The aims of this study are (1) to explore the acceptability and feasibility of the Unified Protocol for individuals who experience Misophonia and (2) to examine whether this treatment helps reduce symptoms associated with Misophonia.
Primary Outcome
The CEQ is a 6-item measure that asks patients about their perceptions of treatment.
Conditions Studied
Interventions
- BEHAVIORAL Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
- BEHAVIORAL Revised Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-12-21 |
| Est. Completion | 2022-08-04 |
| Phase | NA |
What the finished NCT04612374 record still lists
NCT04612374 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 56-participant average among 7 other Misophonia trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Misophonia appearing as the primary indexed condition, and to 2 interventions - of which Unified Protocol for Transdiagnostic Treatment of Emotional Disorders is the first listed.
NCT04612374 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT04612374 about?
NCT04612374 is a clinical study titled "Exploring the Acceptability and Efficacy of a Transdiagnostic Treatment for Misophonia". Despite increasing recognition of misophonia, there are currently no evidence-based treatments to help those who are suffering. Therefore, the primary purpose of this study is to assess the acceptability, feasibility, and preliminary efficacy of a treatment for misophonia. This study will be conduct...
What is the current status of trial NCT04612374?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2020-12-21. Estimated completion is 2022-08-04.
What conditions does trial NCT04612374 study?
This clinical trial studies the following conditions: Misophonia.
What interventions are being tested in trial NCT04612374?
The interventions under investigation include: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (BEHAVIORAL), Revised Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (BEHAVIORAL).
Who is sponsoring clinical trial NCT04612374?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04612374 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Misophonia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Using Neurostimulation to Accelerate Change in Misophonia: a Pilot Study
RECRUITING · NA
-
Transcranial Magnetic Stimulation in Misophonia
RECRUITING · NA
-
Mindfulness Application Effects on Mental Health Symptoms in Children With Severe Tinnitus and Misophonia
RECRUITING · NA
-
Digital Intervention for Adults With Misophonia: A Randomized Controlled Trial
RECRUITING · NA
-
Psychological Intervention for Misophonia
ACTIVE NOT RECRUITING · NA
-
Identifying the Optimal Neural Target for Misophonia Interventions
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI